Design, synthesis, and evaluation of dual‐target inhibitors for the treatment of Alzheimer's disease
Archiv der Pharmazie · 2024
DOI: 10.1002/ardp.202300693 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Jingfang Zhai und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Advanced Drug Delivery System, Key Lab for Rare & Uncommon Diseases of Shandong Province, Key Laboratory for Biotechnology…. Hauptthemen laut MEDLINE: Alzheimer Disease, Zebrafish, Cholinesterase Inhibitors, Drug Design. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: The Spring Sunshine Program is a project initiated by the Ministry of Education of China, Shandong Province Science and Technology Small and Medium Enterprises Innovation Ability Enhancement Project.
Themen: Demenz
Abstract (Originalsprache)
Aβ 1−42 and acetylcholinesterase (AChE) are two key therapeutic targets for Alzheimer's disease (AD). The purpose of this study is to develop a dual‐target inhibitor that inhibits both of these targets by fusing the chemical structure of baicalein and donepezil. Among them, we modified the structure of baicalein to arylcoumarin, synthesized three kinds of structural compounds, and evaluated their biological activities. The results showed that compound 3b had the strongest inhibitory effect on AChE (IC 50 = 0.05 ± 0.02 µM), which was better than those of donepezil and baicalein. In addition, compound 3b has a strong ability to inhibit the aggregation of Aβ 1−42 and protect nerve cells, and it can also penetrate the blood–brain barrier well. Using a zebrafish behavioral analyzer test, it was found that compound 3b can alleviate the behavioral effects of AlCl 3 ‐induced zebrafish larval movement retardation, which has a certain guiding significance for simulating the movement disorders of AD patients. In summary, compound 3b is expected to become a multifunctional agent for treating and alleviating the symptoms of AD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Key Laboratory of Advanced Drug Delivery System, Key Lab for Rare & Uncommon Diseases of Shandong Province, Key Laboratory for Biotechnology Drugs of National Health Commission (Shandong Academy of Medical Scie…
- Jinan Shangcheng Pharmatech. Co. Ltd., Jinan, China.
- Jiangsu Second Chinese Medicine Hospital & The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Förderung
- The Spring Sunshine Program is a project initiated by the Ministry of Education of China
- Shandong Province Science and Technology Small and Medium Enterprises Innovation Ability Enhancement Project
Zitieren
APA
Zhai, J., Hao, C., Wang, X., Cao, Y., Pan, Y., Zhou, M., Sun, J., & Li, C. (2024). Design, synthesis, and evaluation of dual‐target inhibitors for the treatment of Alzheimer's disease. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202300693
Vancouver
Zhai J, Hao C, Wang X, Cao Y, Pan Y, Zhou M, et al. Design, synthesis, and evaluation of dual‐target inhibitors for the treatment of Alzheimer's disease. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202300693
BibTeX
@article{Zhai2024,
author = {Zhai, Jingfang and Hao, Canhua and Wang, Xiaojing and Cao, Yuexing and Pan, Yinbo and Zhou, Min and Sun, Jie and Li, Chuanyou},
title = {Design, synthesis, and evaluation of dual‐target inhibitors for the treatment of Alzheimer's disease},
journal = {Archiv der Pharmazie},
year = {2024},
doi = {10.1002/ardp.202300693}
}
EUVIMED